3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
161
Neoplasm Metastasis
27
Neoplasms
25
Breast Neoplasms, Male
15
Brain Neoplasms
14
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Stomach Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Prostatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Glioblastoma
5
Carcinoma, Non-Small-Cell Lung
5
Esophageal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Salivary Gland Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Gliosarcoma
3
Glioma
3
Gallbladder Neoplasms
3
Ependymoma
3
Carcinoma, Squamous Cell
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Osteitis Deformans
2
Interventions
Neoadjuvant Therapy
1
Lapatinib
1
Epirubicin
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Oesophagogastric Cancer
×
Lapatinib
×
Clear all
NCT00450203
2016-12-01
ST03
Medical Research Council
Phase 2/3
Unknown
1,103 enrolled